Tag: entrepreneurs
-
Neuro Biomarkers, Home EEG Assessed in Upcoming Trial
A digital biomarkers company and developer of neuroscience analytics are collaborating on a study of EEG measurements and algorithms with a wearable device at home.
-
Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds.
-
Infographic – U-Turn on A.I. Venture Funds in Q1
Both the total investment dollars and number of venture deals in Q1 2023 are the lowest single quarter totals since 2019.
-
Brain-Computer Device Company Gains $33M in Early Funds
A company creating brain-computer interface devices to help people with disabling communications impairments is raising $33 million in its first venture round.
-
Measles-Rubella Patch Vaccine Shown Effective as Injection
A clinical trial shows a peel-and-stick patch device is as effective as a standard syringe injection in delivering a vaccine that protects against measles and rubella.
-
Biotech, Janssen Partner on Ultrasound for Gene Therapy
A developer of ultrasound bubbles to assist gene therapies is studying use of the technology with Janssen Pharmaceuticals for delivering DNA and RNA treatments.
-
Rare Disease Search Adds Large Language Model A.I.
A company offering a search engine to help diagnose rare diseases is integrating generative models from Open AI into its artificial intelligence algorithms.
-
Infographic – Climate Start-Ups Still Gaining Venture Funds
Despite a sharp downturn in venture dollars from 2021, new climate and weather forecasting companies continue to attract investments at historically high rates.
-
Quantum Technology Start-Up Accelerator Unveiled
A business incubator is underway to help start-up enterprises in Denmark working in quantum technologies, particularly with defense-related applications.
-
Biotech to Design Disease-Blocking Drugs, Gains $75M
A new company that says it can stop disease-causing proteins from forming in cells began public operations today, and is raising $75 million in its first venture round.